E Royo-Rubio1,2, I Rodríguez-Izquierdo1,2, M Moreno-Domene3, T Lozano-Cruz4,5, F J de la Mata4,5, R Gómez4,5, M A Muñoz-Fernández6, J L Jiménez7. 1. Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), Instituto Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish HIV HGM BioBanco, Madrid, Spain. 2. Plataforma de Laboratorio (Inmunología), HGUGM, IiSGM, Spanish HIV HGM BioBank, Madrid, Spain. 3. Laboratorio Dosimetría Biológica, HGUGM, IiSGM, Madrid, Spain. 4. Departmento Química Orgánica Y Química Inorgánica E Instituto de Investigación Química "Andrés M. del Río″ (IQAR), Universidad de Alcalá (IRYCIS), Campus Universitario, 28871, Madrid, Spain. 5. Networking Research Center On Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN, Madrid, Spain. 6. Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), Instituto Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish HIV HGM BioBanco, Madrid, Spain. mmunoz.hgugm@salud.madrid.org. 7. Plataforma de Laboratorio (Inmunología), HGUGM, IiSGM, Spanish HIV HGM BioBank, Madrid, Spain. joseluis.jimenez@salud.madrid.org.
Abstract
BACKGROUND: The appearance of resistance against new treatments and the fact that HIV-1 can infect various cell types and develop reservoirs and sanctuaries makes it necessary to develop new therapeutic approaches to overcome those failures. RESULTS: Studies of cytotoxicity, genotoxicity, complexes formation, stability, resistance, release and particle size distribution confirmed that G2-SN15-PEG, G3-SN31-PEG, G2-SN15-PEG-FITC and G3-SN31-PEG-FITC dendrimers can form complexes with miRNAs being biocompatible, stable and conferring protection to these nucleic acids. Confocal microscopy and flow cytometry showed effective delivery of these four dendrimers into the target cells, confirming their applicability as delivery systems. Dendriplexes formed with the dendrimers and miRNAs significantly inhibited HIV-1 infection in PBMCs. CONCLUSIONS: These dendrimers are efficient delivery systems for miRNAs and they specifically and significantly improved the anti-R5-HIV-1 activity of these RNA molecules.
BACKGROUND: The appearance of resistance against new treatments and the fact that HIV-1 can infect various cell types and develop reservoirs and sanctuaries makes it necessary to develop new therapeutic approaches to overcome those failures. RESULTS: Studies of cytotoxicity, genotoxicity, complexes formation, stability, resistance, release and particle size distribution confirmed that G2-SN15-PEG, G3-SN31-PEG, G2-SN15-PEG-FITC and G3-SN31-PEG-FITC dendrimers can form complexes with miRNAs being biocompatible, stable and conferring protection to these nucleic acids. Confocal microscopy and flow cytometry showed effective delivery of these four dendrimers into the target cells, confirming their applicability as delivery systems. Dendriplexes formed with the dendrimers and miRNAs significantly inhibited HIV-1 infection in PBMCs. CONCLUSIONS: These dendrimers are efficient delivery systems for miRNAs and they specifically and significantly improved the anti-R5-HIV-1 activity of these RNA molecules.
Authors: M Sylla; O Dolo; A I Maiga; F T Traore; Y A Coulibaly; J Togo; D B Fofana; F Dicko-Traore; S Doumbia; S Orsega; S Diallo; R L Murphy; V Calvez; A G Marcelin Journal: Arch Pediatr Date: 2019-07-12 Impact factor: 1.180
Authors: James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson Journal: Nat Nanotechnol Date: 2014-05-11 Impact factor: 39.213
Authors: Seth C Inzaule; Michael R Jordan; George Bello; Nellie Wadonda-Kabondo; Salou Mounerou; Innocent A Mbulli; Sulaimon A Akanmu; Adolfo Vubil; Gillian Hunt; Pontiano Kaleebu; Simangele Mthethwa-Hleza; Janet Dzangare; Patrick Njukeng; Martina Penazzato; Tobias F Rinke de Wit; Susan H Eshleman; Silvia Bertagnolio Journal: AIDS Date: 2020-08-01 Impact factor: 4.177
Authors: Clementine Wallet; Marco De Rovere; Jeanne Van Assche; Fadoua Daouad; Stéphane De Wit; Virginie Gautier; Patrick W G Mallon; Alessandro Marcello; Carine Van Lint; Olivier Rohr; Christian Schwartz Journal: Front Cell Infect Microbiol Date: 2019-10-24 Impact factor: 5.293
Authors: Daniel B Reeves; Elizabeth R Duke; Thor A Wagner; Sarah E Palmer; Adam M Spivak; Joshua T Schiffer Journal: Nat Commun Date: 2018-11-16 Impact factor: 17.694
Authors: Jon Cantero-Pérez; Judith Grau-Expósito; Carla Serra-Peinado; Daniela A Rosero; Laura Luque-Ballesteros; Antonio Astorga-Gamaza; Josep Castellví; Tamara Sanhueza; Gustavo Tapia; Belen Lloveras; Marco A Fernández; Julia G Prado; Josep M Solé-Sedeno; Antoni Tarrats; Carla Lecumberri; Laura Mañalich-Barrachina; Cristina Centeno-Mediavilla; Vicenç Falcó; Maria J Buzon; Meritxell Genescà Journal: Nat Commun Date: 2019-10-18 Impact factor: 14.919
Authors: Elena Royo-Rubio; Vanessa Martín-Cañadilla; Marco Rusnati; Maria Milanesi; Tania Lozano-Cruz; Rafael Gómez; José Luís Jiménez; Maria Ángeles Muñoz-Fernández Journal: Pharmaceutics Date: 2022-02-28 Impact factor: 6.321